Autor segons l'article: Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Mégarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari FS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Erikstrup C; Condino-Neto A; Prando C; Bondarenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; StJames's Hospital; SARS CoV2 Interest Group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank Investigators; COVID Human Genetic Effort; CP-COVID-19 Group; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement Français du Sang Study group; Anderson MS; Boisson B; Béziat V; Zhang SY; Andreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Burdet C; Bouadma L; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Casanova JL; Abel L; Cobat A HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; StJames's Hospital; SARS CoV2 Interest Group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank Investigators; COVID Human Genetic Effort; CP-COVID-19 Group; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement Français du Sang Study group
Departament: Medicina i Cirurgia
Autor/s de la URV: Auguet Quintillà, Maria Teresa
Paraules clau: Type i ifns Relative risk Infection fatality rate Covid-19 Autoantibodies
Resum: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and ≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death.
Àrees temàtiques: Zootecnia / recursos pesqueiros Saúde coletiva Química Psicología Odontología Multidisciplinary sciences Multidisciplinary Medicina veterinaria Medicina iii Medicina ii Medicina i Matemática / probabilidade e estatística Interdisciplinar Geografía Geociências General o multidisciplinar Farmacia Engenharias iv Engenharias iii Engenharias ii Engenharias i Educação física Ciencias sociales Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciências agrárias i Ciência da computação Biotecnología Biodiversidade Astronomia / física Antropologia / arqueologia Anthropology
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: mariateresa.auguet@urv.cat
Identificador de l'autor: 0000-0003-0396-6428
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.pnas.org/doi/10.1073/pnas.2200413119
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Proceedings Of The National Academy Of Sciences Of The United States Of America. 119 (21): e2200413119-e2200413119
Referència de l'ítem segons les normes APA: Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R (2022). The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings Of The National Academy Of Sciences Of The United States Of America, 119(21), e2200413119-e2200413119. DOI: 10.1073/pnas.2200413119
DOI de l'article: 10.1073/pnas.2200413119
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2022
Tipus de publicació: Journal Publications
Repositori URV